It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Glycosylation of proteins and lipids in viruses and their host cells is important for viral infection and is a target for antiviral therapy. Hepatitis B virus (HBV) is a major pathogen that causes acute and chronic hepatitis; it cannot be cured because of the persistence of its covalently closed circular DNA (cccDNA) in hepatocytes. Here we found that Pholiota squarrosa lectin (PhoSL), a lectin that specifically binds core fucose, bound to HBV particles and inhibited HBV infection of a modified human HepG2 cell line, HepG2-hNTCP-C4, that expresses an HBV receptor, sodium taurocholate cotransporting polypeptide. Knockout of fucosyltransferase 8, the enzyme responsible for core fucosylation and that aids receptor endocytosis, in HepG2-hNTCP-C4 cells reduced HBV infectivity, and PhoSL facilitated that reduction. PhoSL also blocked the activity of epidermal growth factor receptor, which usually enhances HBV infection. HBV particles bound to fluorescently labeled PhoSL internalized into HepG2-hNTCP-C4 cells, suggesting that PhoSL might inhibit HBV infection after internalization. As PhoSL reduced the formation of HBV cccDNA, a marker of chronic HBV infection, we suggest that PhoSL could impair processes from internalization to cccDNA formation. Our finding could lead to the development of new anti-HBV agents.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Osaka University Graduate School of Medicine, Department of Molecular Biochemistry and Clinical Investigation, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971); Osaka University, Laboratory of Single Molecule Biology, Graduate School of Frontier Biosciences, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)
2 Osaka University Graduate School of Medicine, Department of Molecular Biochemistry and Clinical Investigation, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971); Osaka University Graduate School of Medicine, Division of Virology, Department of Microbiology and Immunology, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)
3 Osaka University Graduate School of Medicine, Department of Molecular Biochemistry and Clinical Investigation, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)
4 Osaka University, Applied Microbiology Laboratory, International Center for Biotechnology, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)
5 Osaka University Graduate School of Medicine, Department of Advanced Metabolic Hepatology, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)
6 Osaka University, Laboratory of Single Molecule Biology, Graduate School of Frontier Biosciences, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)
7 Osaka University Graduate School of Medicine, Division of Virology, Department of Microbiology and Immunology, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)